New data presented at EAU 2021 highlight the effects of blue light cystoscopy on the detection and recurrence of bladder cancer

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬


img

Oslo, Norway, July 13, 2021 /PRNewswire/ — Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces highlights of a successful virtual conference of the European Association of Urology, continuing the steady stream of new scientific data presented on the importance of Blue Light Cystoscopy (BLC )®) in the management of bladder cancer.

The annual EAU meeting is one of the largest international gatherings on the urology calendar and showcases the latest and most relevant knowledge in the field of urology. This year’s event was held virtually on July 8-12, 2021. Two poster presentations in the EAU’s scientific program feature the procedure for blue light cystoscopy:

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬

Poster 0716: Early PDD cystoscopy after BCG induction for high-risk non-muscle-invasive bladder cancer significantly increased the detection of BCG-refractory tumors

This presentation focused on a trial comparing the use of white light and blue light cystoscopy with the respective detection rates of BCG-refractory tumors. The study included 136 consecutive patients with high-risk non-muscle-invasive bladder cancer (NMIBC) diagnosed by: January 2017 to Dec 2020. All patients underwent initial BLC TURBT* and resumed TURBT as needed, followed by full dose of BCG.

Within 8 weeks of induction, all patients had both white light and blue light cystoscopy to assess the presence of bladder cancer with the following results: Bladder cancer was diagnosed in 32 of 136 patients (24%). In the patients with bladder cancer, thirteen BCG-refractory tumors were detected with WL, and 14 additional BCG-refractory tumors were detected with PDD, leading to a change in the management of their NMIBC.

The authors concluded that systematic use of blue light PDD after BCG induction increased the detection of BCG-refractory tumors and led to significant change in the treatment of high-risk NMIBC.

Read the full abstract on the conference website: https://resource-centre.uroweb.org/resource-centre/EAU21/221514/Abstract/

Poster 0717: Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer

This presentation included a systematic review and meta-analysis to assess the effect of blue light photodynamic diagnosis (PDD) compared to white light cystoscopy on recurrence rates in patients diagnosed with NMIBC. 12 Randomized Controlled Trials (RCTs) were included in the analysis, looking at the outcomes of the recurrence rate at 12 and 24 months. PDD was found to reduce recurrence at both time points. The authors concluded that this meta-analysis provides high-quality evidence of a moderate confidence assessment for the efficacy of blue light PDD in reducing recurrence rates and improving recurrence-free survival, compared to white light, in NMIBC. This effect is observed over a period of at least 2 years and appears to persist for up to 5 years.

Read the full abstract on the conference website: https://resource-centre.uroweb.org/resource-centre/EAU21/222525/Abstract/

“These new research findings continue to highlight the importance of performing a more complete TURBT using Blue Light Cystoscopy in the treatment of bladder cancer, and also demonstrate the strong interest of the scientific community in investigating the BLC procedure in NMIBC management. has been shown to clinically increase TURBT quality, more accurately assess disease for treatment, and enable better monitoring of recurrence, supporting its long-term utility in helping to improve the lives of patients with bladder cancer,” said Dan Schneider, President and CEO of Photocure.

“As we continue to broaden BLC’s exposure to Hexvix, Europe, it is a privilege to attend the EAU conference virtually and see so much enthusiasm in offering this important product and procedure to new users in Europeadded Susanne Strauss, Vice President and General Manager Europe.

*TURBT: transurethral resection of bladder tumors

Note for editors:

All trademarks mentioned in this press release are protected by law and are registered trademarks of Photocure ASA

About bladder cancer

Bladder cancer is the seventh most common cancer worldwide with 1 720 000 prevalent cases (prevalence rate after 5 years)1a, 573,000 new cases and more than 200,000 deaths per year in 2020.1b

Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with an average of 61% in the first year and 78% over five years.2 Bladder cancer has the highest lifetime treatment cost per patient of all cancers.3

Bladder cancer is a costly, potentially progressive disease that requires patients to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and treatment of bladder cancer, for the benefit of both patients and health care systems.

Bladder cancer is classified into two types, non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion into the bladder wall. NMIBC remains in the innermost layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer has grown into deeper layers of the bladder wall. These cancers, which include the T2, T3, and T4 subtypes, are more likely to spread and more difficult to treat.4

1 Globocan. a) 5-year prevalence / b) incidence/death by population. Available at: https://gco.iarc.fr/today, enter [April 2021].
2 Babjuk M, et al. Eur Urol. 2019; 76 (5): 639-657
3 Sievert KD et al. World J Urol 2009;27:295-300
4 bladder cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix®/cysview® (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, causing them to glow bright pink during blue light cystoscopy (BLC).®). BLC with Hexvix/Cysview improves tumor detection and leads to more complete resection, fewer residual tumors and better management decisions.

Cysview is the trade name in the US and Canada, Hexvix is ​​the trade name in all other markets. Photocure commercializes Cysview/Hexvix directly in the US and Europe, and has strategic partnerships for the commercialization of Hexvix/Cysview in China, Canada, Chili, Australia and New Zealand. Please refer to: https://photocure.com/partnering-with-photocure/our-partners/ for more information about our commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, which makes cancer cells glow bright pink, has led to better health outcomes for patients around the world. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, visit us at: www.photocure.com, www.hexvix.com, and www.cysview.com.

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
E-mail: [email protected]

Erik Dahl
Finance Director
Photocure ASA
Phone: +4745055000
E-mail: [email protected]

David Moskowitz
Head of Investor Relations
Phone: +1 202 280 0888
E-mail: [email protected]

Media and IR questions:

Geir Bjorlo
Corporate Communications (Norway)
Phone: +47 91540000
E-mail: [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/photocure/r/photocure–new-data-presented-at-eau-2021-highlight-the-effects-of-blue-light-cystoscopy-on-detectio,c3383793

The following files are available for download:

SOURCE Photo Treatment

Watch Free Movies and TV shows Apps

🎬📺 Free Movies and Free TV Shows! 🎭🎬

This div height required for enabling the sticky sidebar